Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ASCENDIS PHARMA A/S

(ASND)
  Report
Delayed Nasdaq  -  04:00:01 2023-02-07 pm EST
116.35 USD   +1.93%
02/07Ascendis Pharma Announces Full Year 2022 Financial Results and Business Update Conference Call on February 16
AQ
01/18Tech Stocks Lead European Equities Modestly Higher in Wednesday Trading
MT
01/17Pharma Stocks Lead European Equities Higher in Tuesday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
All news about ASCENDIS PHARMA A/S
02/07Ascendis Pharma Announces Full Year 2022 Financial Results and Business Update Conferen..
AQ
01/18Tech Stocks Lead European Equities Modestly Higher in Wednesday Trading
MT
01/17Pharma Stocks Lead European Equities Higher in Tuesday Trading
MT
01/17SVB Securities Adjusts Price Target on Ascendis Pharma to $163 From $148, Maintains Out..
MT
01/10BioAtla Sees Dosing of First Patient in Mid-Stage Part 2 Study in Soft Tissue Cancer Th..
MT
01/09Transcript : Ascendis Pharma A/S Presents at 41st Annual J.P. Morgan Healthca..
CI
01/09European Equities Begin Week With Sharp Rise
MT
01/09Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K
PU
01/08Ascendis Pharma Provides Update on Vision 3x3 Strategic Roadmap at 41st Annual J.P. Mor..
AQ
01/04Online Enrollment Now Open for Physicians Requesting Expanded Access to Ascendis Pharma..
AQ
01/03Ascendis Pharma A/s : Articles of Association - Form 6-K
PU
01/03Wells Fargo Boosts Price Target on Ascendis Pharma to $177 From $169, Keeps Overweight ..
MT
01/03Ascendis Pharma to Present at the 41st AnnualáJ.P. Morgan Healthcare Conference
AQ
2022Ascendis Pharma A/s : Articles of Association - Form 6-K
PU
2022After Seesaw Opening, European Equities Little Changed in Monday Trading
MT
2022Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K
PU
2022Ascendis Pharma A/S Announces U.S. Food & Drug Administration Allows to Initiate an Exp..
CI
2022Ascendis Pharma to Initiate TransCon™ PTH U.S. Expanded Access Program for Adult ..
AQ
2022European Equities Nudge Higher on Slightly Lower Euro Area Inflation
MT
2022Ascendis Pharma to Participate in the 5th Annual Evercore ISI HealthCONx Conference
AQ
2022European Equities Flat in Choppy Trade Wednesday as Geopolitical Tensions Weigh
MT
2022Morgan Stanley Adjusts Price Target on Ascendis Pharma to $148 From $146, Maintains Ove..
MT
2022Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines A..
AQ
2022European ADRs Continue to Trend Higher in Monday Trading
MT
2022Ascendis Pharma Submits Marketing Authorization Application in EU for Hypoparathyroidis..
MT
2022Dose Escalation Data from transcendIT-101 Ascendis Pharma's Phase 1/2 Trial of TransCon..
AQ
2022Once-Weekly TransCon CNP Achieved Primary Efficacy Objective, with Superiority at 100 -..
AQ
2022Transcript : Ascendis Pharma A/S - Special Call
CI
2022Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K
PU
2022Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines A..
AQ
2022Ascendis Pharma Submits Marketing Authorization Application to the European Medicines A..
CI
2022Wedbush Raises Price Target on Ascendis Pharma to $164 From $151, Keeps Outperform Rati..
MT
2022Ascendis Pharma A/s : TransCon™ CNP ACcomplisH Trial Topline Results
PU
2022Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective, with Superiority a..
AQ
2022TransCon CNP Achieves Primary Efficacy Objective, with Superiority at 100 Ág/kg/week, i..
CI
2022ADRs End Higher; Ascendis Pharma, ASML Holding Trade Actively
DJ
2022Ascendis Pharma A/s : TransCon™ TLR7/8 Agonist Initial Results from Dose Escalation ..
PU
2022Dose Escalation Data from transcendIT-101, Ascendis Pharma's Phase 1/2 Trial of TransCo..
AQ
2022Dose Escalation Data from transcendIT-101, Ascendis Pharma’s Phase 1/2 Trial of Tr..
CI
2022Ascendis Pharma A/s : Articles of Association - Form 6-K
PU
2022Wells Fargo Adjusts Price Target on Ascendis Pharma to $169 From $172, Maintains Overwe..
MT
2022European Bourses Close Mostly Lower as EU Unemployment Rate Declines
MT
2022Citigroup Adjusts Price Target on Ascendis Pharma A/S to $163 From $157, Maintains Buy ..
MT
2022European ADRs Regain Some Early Losses on Thursday
MT
2022Credit Suisse Adjusts Ascendis Pharma's Price Target to $130 From $123, Keeps Outperfor..
MT
2022Morgan Stanley Adjusts Price Target on Ascendis Pharma A/S to $146 From $148, Maintains..
MT
2022Oppenheimer Adjusts Ascendis Pharma Price Target to $150 From $144, Maintains Outperfor..
MT
2022Wedbush Raises Ascendis Pharma's Price Target to $151 From $144 After Q3 SKYTROFA Sales..
MT
2022Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K
PU
2022Transcript : Ascendis Pharma A/S, Q3 2022 Earnings Call, Nov 02, 2022
CI
2022Earnings Flash (ASND) ASCENDIS PHARMA Reports Q3 Revenue EUR15.3M
MT
2022Ascendis Pharma Reports Third Quarter 2022 Financial Results
AQ
2022Ascendis Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ende..
CI
2022FDA Accepts for Priority Review Ascendis Pharma's NDA for TransCon PTH in Adult Patient..
AQ
2022Ascendis Pharma Says FDA Grants Priority Review to Hypoparathyroidism Treatment TransCo..
MT
2022Ascendis Pharma Gets FDA Acceptance for Priority Review of TransCon PTH
DJ
2022Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K
PU
2022FDA Accepts for Priority Review Ascendis Pharma's NDA for TransCon™ PTH in Adult ..
AQ
2022Ascendis Pharma A/S Announces FDA Accepts for Priority Review Its NDA for TransCon(TM) ..
CI
2022Ascendis Pharma A/S Announces Third Quarter 2022 Financial Results and Business Update ..
AQ
2022Goldman Sachs Initiates Coverage on Ascendis Pharma With Buy Rating, $174 Price Target
MT
2022European ADRs Move Higher in Thursday Trading
MT
2022Ascendis Pharma A/s : Articles of Association - Form 6-K
PU
2022European ADRs Move Slightly Lower in Wednesday Trading
MT
2022European ADRs Move Sharply Lower in Wednesday Trading
MT
2022Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K
PU
2022European ADRs Surge Higher in Monday Trading
MT
2022Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for transcendIT..
AQ
2022Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for TranscendIT..
CI
2022Ascendis Pharma A/s : Articles of Association - Form 6-K
PU
2022Ascendis Pharma Added to Wedbush Best Ideas List
MT
2022European ADRs Move Lower in Thursday Trading
MT
2022Wells Fargo Adjusts Ascendis Pharma Price Target to $172 From $167, Maintains Overweigh..
MT
2022Ascendis Pharma A/s : Articles of Association - Form 6-K
PU
2022Transcript : Ascendis Pharma A/S Presents at Morgan Stanley 20th Annual Globa..
CI
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on ASCENDIS PHARMA A/S